Albuterol Extended-Release Tablets and Tenormin Injection
Determining the interaction of Albuterol Extended-Release Tablets and Tenormin Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using atenolol together with albuterol may reduce the benefits of both medications, since they have opposing effects in the body. In addition, atenolol can sometimes cause narrowing of the airways, which may worsen your breathing problems or trigger severe asthmatic attacks. You may not be able to use atenolol if you have frequent asthma attacks or severe asthma or COPD (chronic obstructive pulmonary disease), or you may need a dose adjustment and more frequent monitoring of your lung function to safely use both medications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. Let your doctor know if you experience wheezing, shortness of breath, chest tightness, or other breathing difficulties during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors. Numerous single- and multiple-dose studies have been conducted in asthmatic and COPD patients with various cardioselective beta-blockers, including acebutolol, atenolol, bisoprolol, celiprolol, metoprolol, and nebivolol. Some reported no significant effects on pulmonary function or bronchodilator response to beta-2 agonists, while others reported some negative effects on pulmonary function and/or airway hyperresponsiveness. Overall, a meta-analysis of more than two dozen studies found that use of cardioselective beta-blockers in patients with mild to moderate reversible airway disease produced no adverse respiratory effects or decreased responsiveness to beta-2 agonists in the short term. A meta-analysis of 19 studies conducted in patients with COPD by the same group of investigators reported similar results. However, little data exist regarding their safety during chronic use or use in patients with severe respiratory disease. There have been reports of worsening asthma and bronchospasm in patients receiving cardioselective beta-blockers including betaxolol (both systemic and ophthalmic) and esmolol. Several studies have suggested enhanced bronchosparing effects of celiprolol over other cardioselective beta-blockers due to its partial beta-2 agonistic and alpha-2 blocking activities. However, one study found no difference between celiprolol and nebivolol. A few studies also suggested a lower degree of beta-1 selectivity for acebutolol compared to other cardioselective beta-blockers. The clinical significance is unknown.
MANAGEMENT: Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations. The dosage should start low, preferably in divided doses to avoid the higher plasma levels associated with longer dosing intervals, and titrated slowly according to therapeutic response and pulmonary function. Patients should be advised to contact their physician if they experience worsening of respiratory symptoms, which would warrant a reevaluation of the appropriateness of beta-blocker therapy. Cardioselective beta-blockers should be used with extreme caution, if at all, in patients prone to frequent exacerbations of their respiratory disease.
- Hollenberg NK "The role of beta-blockers as a cornerstone of cardiovascular therapy." Am J Hypertens 18(12 Pt 2) (2005): 165S-168S
- Baselli LM, Oswald MA, Nashelsky JM "Do beta-blockers worsen respiratory status for patients with COPD?" J Fam Pract 54 (2005): 472-3
- Cazzola M, Noschese P, D'Amato M, D'Amato G "Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma." Chest 118 (2000): 1322-6
- Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80
- Gold MR, Dec GW, Cocca-Spofford D, Thompson BT "Esmolol and ventilatory function in cardiac patients with COPD." Chest 100 (1991): 1215-8
- Salpeter SR, Ormiston TM, Salpeter EE "Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis." Ann Intern Med 137 (2002): 715-25
- Chodosh S, Tuck J, Blasucci DJ "The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics." J Cardiovasc Pharmacol 11 (1988): s18-24
- Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE "Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation." Clin Pharmacol Ther 25 (1979): 536-40
- Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB "Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy." Ann Pharmacother 28 (1994): 701-3
- De Bono G, Kaye CM, Roland E, Summers AJ "Acebutolol: ten years of experience." Am Heart J 109 (1985): 1211-3
- van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R "Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers." Chest 127 (2005): 818-24
- Cazzola M, Noschese P, D'Amato G, Matera MG "The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction." Chest 121 (2002): 230-41
- Rasch D, Holt J, Wilson M, Smith RB "Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol." Anesthesiology 59 (1983): 583-5
- Craig TJ "Drugs to be used with caution in patients with asthma." Am Fam Physician 54 (1996): 947-53
- Tafreshi MJ, Weinacker AB "Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma." Pharmacotherapy 19 (1999): 974-8
- Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A "Effects of esmolol on airway function in patients with asthma." J Clin Pharmacol 26 (1986): 169-74
- Ashrafian H, Violaris AG "Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint." Prim Care Respir J 14 (2005): 236-41
- Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60
- Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D "Cardioselective beta-blockers for chronic obstructive pulmonary disease." Cochrane Database Syst Rev 2 (2002): CD0003566
- Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A "Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction." Br J Clin Pharmacol 26 (1988): 279-84
- Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70
- Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F "Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin." J Cardiothorac Anesth 3 (1989): 748-51
- Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM "The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects." Am Rev Respir Dis 133 (1986): 264-8
- Brooks AM, Burden JG, Gillies WE "The significance of reactions to betaxolol reported by patients." Aust N Z J Ophthalmol 17 (1989): 353-5
- Brooks AM, Gillies WE "Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects." Drugs Aging 2 (1992): 208-21
- Chafin CC, Soberman JE, Demirkan K, Self T "Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?." Cardiology 92 (1999): 99-105
Generic Name: albuterol
Brand name: ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin HFA, Accuneb, ProAir Digihaler, Proventil, VoSpire ER
Synonyms: Albuterol Inhalation, Albuterol
Generic Name: atenolol
Brand name: Tenormin
Synonyms: Tenormin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Albuterol Extended-Release Tablets-Tenormin Intravenous
- Albuterol Extended-Release Tablets-Tenuate
- Albuterol Extended-Release Tablets-Tenuate Dospan
- Albuterol Extended-Release Tablets-Tepadina
- Albuterol Extended-Release Tablets-Tepadina Injection
- Albuterol Extended-Release Tablets-Tepanil
- Tenormin Injection-Albuterol Inhalation
- Tenormin Injection-Albuterol Inhalation Aerosol
- Tenormin Injection-Albuterol Inhalation Powder
- Tenormin Injection-Albuterol Inhalation Solution
- Tenormin Injection-Albuterol Oral Solution
- Tenormin Injection-Albuterol Sulfate